Wang et al. have reported that the induction of DNA damage by CDK12 inhibition is synergistic with sorafenib treatment in HCC [37], and it shows that the induction of DNA damage combined with sorafenib treatment may be a more effective therapeutical approach in HCC. Here, CDK12 is linked to hepatocellular carcinoma.